Nordea Investment Management AB Has $23.41 Million Position in Bristol Myers Squibb Company $BMY

Key Points

• Nordea Investment Management AB reduced its position in Bristol Myers Squibb by 19.6% in Q2, resulting in ownership of 502,686 shares valued at approximately $23.41 million.
• Recent insider transactions included EVP David V. Elkins selling 56,000 shares at an average price of $47.33, marking a 25.07% decrease in his ownership.
• Bristol Myers Squibb recently declared a quarterly dividend of $0.62 per share, translating to an annualized dividend yield of 5.7% with a payout ratio of 100%.

Nordea Investment Management AB lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 19.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 502,686 shares of the biopharmaceutical company's stock after selling 122,454 shares during the quarter. Nordea Investment Management AB's holdings in Bristol Myers Squibb were worth $23,410,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Trifecta Capital Advisors LLC bought a new position in Bristol Myers Squibb in the second quarter valued at approximately $25,000. REAP Financial Group LLC lifted its stake in Bristol Myers Squibb by 202.8% in the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 428 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in Bristol Myers Squibb in the first quarter valued at approximately $31,000. Accent Capital Management LLC bought a new position in Bristol Myers Squibb in the first quarter valued at approximately $33,000. Finally, CBIZ Investment Advisory Services LLC lifted its stake in Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 231 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares of the company's stock, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.09% of the company's stock.

Analyst Ratings Changes

A number of brokerages have weighed in on BMY. Citigroup reaffirmed a "neutral" rating on shares of Bristol Myers Squibb in a research note on Monday, October 13th. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a research note on Tuesday, August 5th. Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Weiss Ratings reissued a "hold (c-)" rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Finally, Daiwa America lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of "Hold" and a consensus price target of $57.23.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $43.63 on Friday. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The company's fifty day simple moving average is $46.07 and its 200-day simple moving average is $47.47. Bristol Myers Squibb Company has a 12 month low of $42.96 and a 12 month high of $63.33. The firm has a market cap of $88.80 billion, a PE ratio of 17.59, a P/E/G ratio of 2.26 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period in the prior year, the firm posted $2.07 earnings per share. The company's quarterly revenue was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.7%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio is 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.